[A Thoracic Aortic Dissection Case during Treatment with Ramucirumab plus Nab-Paclitaxel]

Gan To Kagaku Ryoho. 2020 Jun;47(6):981-983.
[Article in Japanese]

Abstract

Ramucirumab(RAM)plus nab-paclitaxel(nab-PTX)therapy is a regimen that is recommended for the second round of chemotherapy in recurrent, progressive gastric cancer. We report the first case of a thoracic aortic dissection developed during RAM plus nab-PTX therapy. A 59-year-old male who had undergone a proximal gastrectomy for esophagogastric junction cancer had a recurrence of cancer 6 years later(metastasis to the para-aortic lymph node and left adrenal gland, local recurrence, and multiple bone metastases). He was treated with RAM plus nab-PTX therapy for second-line chemotherapy. On day 9 of the third cycle, he experienced sudden, severe neck pain and visited the outpatient emergency department. Computed tomography detected a Stanford type-A thoracic aortic dissection. However, the patient suffered from a myocardial infarction before the operation, and died. This is the first report of an aortic dissection associated with RAM. Clinicians must be aware of this complication.

Publication types

  • Case Reports

MeSH terms

  • Albumins
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Aortic Dissection* / complications
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Paclitaxel
  • Ramucirumab
  • Stomach Neoplasms* / complications

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Antibodies, Monoclonal, Humanized
  • Paclitaxel